• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

印度中部一家三级眼科医疗机构在 COVID-19 大流行期间对鼻眶脑毛霉菌病及其相关因素的研究。

Study of rhino-orbital-cerebral mucormycosis and its correlates during COVID-19 pandemic in a tertiary eye care institute of central India.

机构信息

Department of Ophthalmology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.

出版信息

Indian J Ophthalmol. 2023 Dec 1;71(12):3669-3676. doi: 10.4103/IJO.IJO_356_23. Epub 2023 Nov 20.

DOI:10.4103/IJO.IJO_356_23
PMID:37991302
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10788766/
Abstract

PURPOSE

To evaluate factors associated with the occurrence of ROCM in COVID-19 patients and to compare its related parameters and outcomes between active and recovered COVID-19 groups.

METHODS

A total of 35 patients of ROCM associated with COVID-19 (active and post-COVID-19) were included. This is an ambispective study with retrospective medical records review for COVID-19 analysis and prospective assessments of ROCM-associated COVID-19 during the second wave of the COVID-19 pandemic. The demographic data, clinical parameters, and outcome were recorded on MS excel sheet, and various parameters were compared between active and recovered COVID-19 groups.

RESULTS

ROCM in recovered COVID-19 group was higher (57.1%) as compared to active COVID-19 (42.9%) (P = 1.00). High occurrence of ROCM was seen in those who had a history of hospitalization due to severity of COVID-19 (n 33, 94.28%), oxygen support (77.14), and received systemic steroids (82.9%). The most common comorbidity was diabetes mellitus (82.9%), and new-onset hyperglycemia was noticed in 17.1% of patients. Exenteration (28.6%) was performed in severe cases who had stage IV ROCM, bilateral, and CNS involvement (RR = 7.2, 95% CI: 2.91 to 18.00). The risk of globe exenteration was 1.35 (0.7-2.29) times higher in recovered COVID-19 group, and mortality was 1.76 (0.72-3.36) times higher in active COVID-19 group.

CONCLUSION

Monitored use of systemic steroids and the prompt management of hyperglycemia in COVID-19 patients are important factors for favorable outcomes with reference to globe salvage and life-saving in ROCM associated with COVID-19. Even recovered COVID-19 patients should be observed for persistent hyperglycemia and occurrence of ROCM.

摘要

目的

评估与 COVID-19 相关的放射性角膜病(ROCm)发生的相关因素,并比较活动期 COVID-19 组与恢复期 COVID-19 组之间的相关参数和结局。

方法

共纳入 35 例与 COVID-19 相关的 ROCm(活动期和 COVID-19 后)患者。这是一项前瞻性研究,回顾性分析 COVID-19 病历,在 COVID-19 大流行的第二波期间前瞻性评估与 COVID-19 相关的 ROCm。将人口统计学数据、临床参数和结局记录在 MS excel 工作表上,并比较活动期 COVID-19 组与恢复期 COVID-19 组之间的各种参数。

结果

与活动期 COVID-19 组(42.9%)相比,恢复期 COVID-19 组 ROCm 发生率更高(57.1%)(P=1.00)。因 COVID-19 严重程度而住院(n=33,94.28%)、接受氧疗(77.14%)和全身使用类固醇(82.9%)的患者中 ROCm 发生率较高。最常见的合并症是糖尿病(82.9%),17.1%的患者出现新发高血糖。在患有 IV 期 ROCm、双侧和 CNS 受累的严重病例中进行了眶内容剜除术(28.6%)(RR=7.2,95%CI:2.91-18.00)。在恢复期 COVID-19 组,眼球摘除的风险增加 1.35 倍(95%CI:0.7-2.29),而活动期 COVID-19 组死亡率增加 1.76 倍(95%CI:0.72-3.36)。

结论

对于 COVID-19 患者,有监测使用全身类固醇和及时处理高血糖是保留眼球和挽救生命的重要因素,这与 COVID-19 相关的 ROCm 有关。即使是恢复期 COVID-19 患者也应注意持续高血糖和 ROCm 的发生。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0fc/10788766/050e6a3835e5/IJO-71-3669-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0fc/10788766/926581711bf0/IJO-71-3669-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0fc/10788766/050e6a3835e5/IJO-71-3669-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0fc/10788766/926581711bf0/IJO-71-3669-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0fc/10788766/050e6a3835e5/IJO-71-3669-g002.jpg

相似文献

1
Study of rhino-orbital-cerebral mucormycosis and its correlates during COVID-19 pandemic in a tertiary eye care institute of central India.印度中部一家三级眼科医疗机构在 COVID-19 大流行期间对鼻眶脑毛霉菌病及其相关因素的研究。
Indian J Ophthalmol. 2023 Dec 1;71(12):3669-3676. doi: 10.4103/IJO.IJO_356_23. Epub 2023 Nov 20.
2
A fungal epidemic amidst a viral pandemic: Risk factors for development of COVID-19 associated rhino-orbital-cerebral mucormycosis in India.真菌性传染病在病毒性传染病大流行期间:印度 COVID-19 相关的鼻眶脑毛霉菌病发病的危险因素。
Orbit. 2023 Feb;42(1):30-41. doi: 10.1080/01676830.2021.2020851. Epub 2022 Feb 22.
3
Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1.印度 2826 例 COVID-19 相关的鼻-眶-脑毛霉菌病的流行病学、临床特征、治疗和结局 - 合作 OPAI-IJO 新冠病毒相关毛霉菌病研究(COSMIC),报告 1。
Indian J Ophthalmol. 2021 Jul;69(7):1670-1692. doi: 10.4103/ijo.IJO_1565_21.
4
Analysis of COVID-19-associated rhino-orbital-cerebral mucormycosis patients in a tertiary care center in Northern India.印度北部一家三级护理中心 COVID-19 相关的鼻眶脑毛霉菌病患者分析。
Indian J Ophthalmol. 2022 Jun;70(6):2163-2168. doi: 10.4103/ijo.IJO_340_22.
5
Rhino-orbito-cerebral mucormycosis and its resurgence during COVID-19 pandemic: A review.COVID-19 大流行期间的鼻-眶-脑毛霉病及其再现:综述。
Indian J Ophthalmol. 2023 Jan;71(1):39-56. doi: 10.4103/ijo.IJO_1219_22.
6
Battling the emerging epidemic of rhino-orbital-cerebral mucormycosis (ROCM) in COVID-19 pandemic: an interventional study.应对新冠疫情期间,发生的新型冠状-眼窝-脑部毛霉菌病(ROCM)流行:一项介入性研究。
Int Ophthalmol. 2023 May;43(5):1571-1580. doi: 10.1007/s10792-022-02556-3. Epub 2022 Oct 23.
7
Cross-sectional study to describe the severity, bio-chemical associations, and final outcomes of COVID-19-associated rhino-orbital-cerebral mucormycosis in a tertiary hospital of East India.在印度东部的一家三级医院进行的横断面研究,旨在描述 COVID-19 相关的鼻-眶-脑毛霉菌病的严重程度、生物化学关联和最终结局。
Indian J Ophthalmol. 2023 May;71(5):2193-2198. doi: 10.4103/IJO.IJO_2507_22.
8
Is mucormycosis the end? A comprehensive management of orbit in COVID associated rhino-orbital-cerebral mucormycosis: preserving the salvageable.是否意味着毛霉菌病的终结?COVID 相关的鼻-眶-脑毛霉菌病的全面管理:保留可挽救的。
Eur Arch Otorhinolaryngol. 2023 Feb;280(2):819-827. doi: 10.1007/s00405-022-07620-3. Epub 2022 Sep 2.
9
Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19.经新冠病毒(COVID-19)感染后继发的鼻眶脑型毛霉菌病(ROCM)患者接受经皮眶后注射两性霉素 B(TRAMB)辅助治疗的结局。
Int Ophthalmol. 2023 Jun;43(6):1919-1926. doi: 10.1007/s10792-022-02591-0. Epub 2022 Nov 24.
10
Spectrum of orbital fat necrosis in rhino-orbital-cerebral mucormycosis in post-COVID-19 patients.COVID-19 后患鼻-眶-脑毛霉菌病患者眶内脂肪坏死的范围。
Indian J Ophthalmol. 2024 Oct 1;72(10):1478-1482. doi: 10.4103/IJO.IJO_2623_23. Epub 2024 Sep 27.

引用本文的文献

1
Survival and prognostic factors in rhino-orbito-cerebral mucormycosis: A 3-year cohort study.鼻眶脑型毛霉菌病的生存及预后因素:一项为期3年的队列研究。
Sci Rep. 2025 May 8;15(1):16088. doi: 10.1038/s41598-025-98926-9.
2
Estimation of the pattern of ocular manifestations, risk factors, and imaging of rhino-orbital-cerebral mucormycosis in COVID-19 patients.新型冠状病毒肺炎患者鼻眶脑型毛霉菌病眼部表现模式、危险因素及影像学评估
J Family Med Prim Care. 2025 Jan;14(1):259-267. doi: 10.4103/jfmpc.jfmpc_1161_24. Epub 2025 Jan 13.

本文引用的文献

1
The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries.COVID-19 相关毛霉病的出现:来自 18 个国家的病例回顾。
Lancet Microbe. 2022 Jul;3(7):e543-e552. doi: 10.1016/S2666-5247(21)00237-8. Epub 2022 Jan 25.
2
COVID-19, Hyperglycemia, and New-Onset Diabetes.新型冠状病毒肺炎、高血糖和新发糖尿病。
Diabetes Care. 2021 Dec;44(12):2645-2655. doi: 10.2337/dc21-1318. Epub 2021 Oct 8.
3
Ocular manifestations of RT-PCR-confirmed COVID-19 cases in a large database cross-sectional study.一项大型数据库横断面研究中经逆转录聚合酶链反应(RT-PCR)确诊的2019冠状病毒病(COVID-19)病例的眼部表现
BMJ Open Ophthalmol. 2021 Sep 22;6(1):e000775. doi: 10.1136/bmjophth-2021-000775. eCollection 2021.
4
Rhino-Orbito-Cerebral-Mucormycosis During the COVID-19 Second Wave in 2021 - A Preliminary Report from a Single Hospital.2021年新冠疫情第二波期间的鼻-眶-脑毛霉菌病——来自一家医院的初步报告
Clin Ophthalmol. 2021 Aug 17;15:3505-3514. doi: 10.2147/OPTH.S324977. eCollection 2021.
5
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.COVID-19 相关毛霉菌病:全球及印度病例报告的系统综述。
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102146. doi: 10.1016/j.dsx.2021.05.019. Epub 2021 May 21.
6
Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1.印度 2826 例 COVID-19 相关的鼻-眶-脑毛霉菌病的流行病学、临床特征、治疗和结局 - 合作 OPAI-IJO 新冠病毒相关毛霉菌病研究(COSMIC),报告 1。
Indian J Ophthalmol. 2021 Jul;69(7):1670-1692. doi: 10.4103/ijo.IJO_1565_21.
7
Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic.新型冠状病毒肺炎大流行期间,一家三级医疗中心收治的鼻眶脑毛霉菌病病例激增。
Front Med (Lausanne). 2021 May 28;8:645270. doi: 10.3389/fmed.2021.645270. eCollection 2021.
8
Viral infiltration of pancreatic islets in patients with COVID-19.新冠病毒对胰腺胰岛的浸润。
Nat Commun. 2021 Jun 10;12(1):3534. doi: 10.1038/s41467-021-23886-3.
9
Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran.COVID-19 患者中的毛霉菌病:来自伊朗的一项横断面描述性多中心研究。
Mycoses. 2021 Oct;64(10):1238-1252. doi: 10.1111/myc.13334. Epub 2021 Jul 1.
10
Rise of the phoenix: Mucormycosis in COVID-19 times.凤凰涅槃:新冠时期的毛霉菌病。
Indian J Ophthalmol. 2021 Jun;69(6):1563-1568. doi: 10.4103/ijo.IJO_310_21.